Every Form 4 that Indivior Pharmaceuticals Inc. (INDV) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow INDV and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full INDV filings page.
Indivior Pharmaceuticals, Inc. (INDV) reported that Chief Accounting Officer Anderson Woodrow D purchased 1,500 shares of its Common Stock on August 27, 2026 in an open market or private transaction at a price of $35.69 per share. Following this transaction, he directly owns 27,638 shares of Indivior common stock.
Indivior Pharmaceuticals, Inc. reports that Chief Accounting Officer Anderson Woodrow D purchased 1,500 shares of common stock on 2026-08-05 at $36.28 per share in an open-market or private transaction. Following this buy, he directly owns 26,138 shares of the company’s common stock.
Indivior Pharmaceuticals, Inc. reports that Chief Scientific Officer Christian Heidbreder conducted an open-market sale of 18,586 shares of common stock at $41.14 per share on July 10, 2026. Following this transaction, he holds 209,337 shares directly. The sale was made pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2026.
Indivior Pharmaceuticals, Inc. reported that Chief Executive Officer Joseph Ciaffoni had performance stock units granted on May 13, 2025 vest at 100%, resulting in 1,266,903 common shares vesting on June 22, 2026. Each unit converted into one share of common stock. To cover related tax withholding obligations, 612,549 of these shares were withheld, and Ciaffoni now holds 790,330 shares of common stock directly. All 1,266,903 performance stock units were fully settled and no such units remain outstanding.
Indivior Pharmaceuticals, Inc. Chief Scientific Officer Christian Heidbreder reported an open-market sale of 18,586 shares of common stock at $38.06 per share. After this transaction on June 11, 2026, he directly holds 227,923 shares. The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted by the reporting person on March 13, 2026, indicating it was scheduled in advance rather than timed discretionarily.
Indivior Pharmaceuticals, Inc. reported that Chief Financial Officer Ryan Preblick sold 36,000 shares of Common Stock in an open-market transaction at $37.70 per share on June 8, 2026. The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on March 6, 2026. Following this transaction, Preblick directly holds 284,751 shares, indicating he retains a substantial equity stake in the company.
Indivior Pharmaceuticals director Juliet Thompson reported routine equity compensation and related tax withholding transactions. She received a grant of 6,518 Restricted Stock Units, each representing one share of common stock, which will vest immediately before the next annual stockholder meeting if she continues serving the company.
To satisfy tax withholding obligations from RSU vesting on May 12, 2026, 1,117 shares of common stock were withheld at a price of $38.28 per share, which is not an open-market sale. After these transactions, Thompson holds 12,973 shares directly and 5,775 shares indirectly through her spouse.
Humphreys Keith reported acquisition or exercise transactions in this Form 4 filing.
Indivior Pharmaceuticals, Inc. director Keith Humphreys reported a compensation-related equity grant. He received 6,518 shares of Common Stock in the form of Restricted Stock Units, with no cash price per share shown in the filing. After this award, he directly holds 16,042 shares of the company’s stock. The RSUs vest on the day immediately before the next annual stockholder meeting following the grant date, as long as he continues serving the company until that vesting date.
Kingsley Stuart A reported acquisition or exercise transactions in this Form 4 filing.
Indivior Pharmaceuticals, Inc. director Stuart A. Kingsley received an equity award of 6,518 shares of common stock in the form of restricted stock units. These RSUs were granted at $0.00 per share as compensation, not through an open-market purchase.
Each RSU represents a right to receive one share of common stock and will vest on the day immediately before the next annual stockholder meeting following the grant date, if Kingsley continues serving the company. After this award, he holds 12,100 shares of Indivior common stock directly.
Indivior Pharmaceuticals, Inc. reported that director Daniel A. Ninivaggi acquired 6,518 shares of common stock through a grant of Restricted Stock Units (RSUs). Each RSU represents the right to receive one share of common stock at vesting.
The RSUs vest on the day immediately preceding the company’s next annual stockholder meeting, subject to his continued service. Following this equity award, Ninivaggi directly owns 27,163 shares of Indivior common stock, reflecting a routine compensation-related increase in his holdings rather than an open‑market purchase.
Ryan Barbara reported acquisition or exercise transactions in this Form 4 filing.
Indivior Pharmaceuticals, Inc. director Ryan Barbara reported receiving a grant of 6,518 shares of common stock in the form of Restricted Stock Units (RSUs) at no cash cost. After this award, the director holds 12,242 common shares directly.
Each RSU represents a contingent right to receive one share of common stock and will vest on the day immediately before the next annual stockholder meeting, as long as the director continues to serve until that date. This is a compensation-related equity award rather than an open‑market purchase or sale.
Stejbach Mark reported acquisition or exercise transactions in this Form 4 filing.
Indivior Pharmaceuticals, Inc. director Mark Stejbach received an equity grant of 6,518 shares of common stock in the form of restricted stock units. The RSUs vest immediately before the next annual stockholder meeting, as long as he continues serving the company, bringing his direct holdings to 27,087 shares.
Wheadon David E. reported acquisition or exercise transactions in this Form 4 filing.
Indivior Pharmaceuticals, Inc. director David E. Wheadon received a grant of 10,430 Restricted Stock Units (RSUs), each representing one share of common stock. The award is compensation rather than a cash purchase, at a stated price of $0.00 per share. Following this grant, his direct holdings total 30,780 shares. The RSUs vest the day before the next annual stockholders’ meeting after the grant date, if he continues serving the company until that vesting date.
Indivior Pharmaceuticals, Inc. Chief Financial Officer Ryan Preblick reported routine equity compensation activity. On March 14, 2026, 6,302 restricted stock units vested and converted into the same number of common shares. To cover tax withholding obligations, 2,843 of these shares were withheld at $31.11 per share, leaving a net increase of 3,459 shares. Following these transactions, Preblick directly holds 320,751 shares of Indivior common stock.
Indivior Pharmaceuticals director Barbara Ryan reported an open-market purchase of common stock. Ryan bought 8 shares at $31.085 per share on March 13, 2026. Following this trade, Ryan directly holds 5,724 shares of Indivior Pharmaceuticals common stock.
Indivior Pharmaceuticals, Inc. director Stuart A. Kingsley bought additional shares of the company in the open market. On March 6, 2026, he purchased 940 shares of Common Stock at an average price of $31.865 per share. Following this open‑market purchase, he directly owns 5,582 shares of Indivior common stock.
Indivior Pharmaceuticals, Inc. director Ryan Barbara reported an open-market purchase of common stock. On March 9, 2026, Ryan Barbara bought 31 shares of Indivior common stock at $32.56 per share. After this trade, the director directly owns 5,716 shares of Indivior common stock.
Indivior Pharmaceuticals, Inc. Chief Accounting Officer Anderson Woodrow D reported equity award vesting and related share movements on March 3, 2026. Performance stock units granted on March 3, 2023 vested at 76.6%, resulting in 18,364 common shares out of a 23,975 target amount, and restricted stock units also vested.
To cover tax withholding tied to these vestings, 8,283 and 2,682 common shares were disposed of at $31.98 per share through tax-withholding transactions, rather than open-market sales. After these derivative conversions and tax withholdings, the reporting person held 24,638 shares of common stock directly.
Indivior Pharmaceuticals, Inc. Chief Financial Officer Ryan Preblick reported equity award activity involving performance stock units and common stock. In 2024, 204,904 shares vested from performance stock units granted on March 3, 2021 and were subject to a further two-year holding period. On March 3, 2026, this holding period ended and 87,597 shares were withheld to satisfy tax withholding obligations. On the same date, 86,949 shares of common stock vested from performance stock units granted on March 3, 2023 after performance conditions were determined to be met at 76.6% of a 113,510 share target. Each performance stock unit represents a contingent right to receive one share of common stock. After these transactions, Preblick held 317,292 shares of Indivior common stock directly.
Indivior Pharmaceuticals, Inc. Chief Legal Officer Jeffrey W. Burris reported the vesting of performance stock units on March 3, 2026. The units vested after performance conditions were determined to be met at 76.6%, resulting in 79,893 common shares vesting from a 104,300 target grant made on March 3, 2023. Each performance stock unit corresponded to one share of common stock. To cover tax withholding obligations from this vesting, 36,032 shares of common stock were disposed of at a price of $31.98 per share, leaving Burris with 71,518 directly owned common shares after these transactions.
Indivior Pharmaceuticals, Inc. Chief Scientific Officer Christian Heidbreder had performance stock units granted on March 3, 2023 vest on March 3, 2026 after performance conditions were determined to be met at 76.6%. This resulted in 101,544 shares of common stock vesting out of a 132,565 target amount, with each unit representing one share. To cover tax withholding related to this vesting, 45,797 shares of common stock were disposed of at $31.98 per share. Following these transactions, Heidbreder directly held 246,509 shares of Indivior common stock.
Indivior Pharmaceuticals, Inc. reported that Chief Accounting Officer Anderson Woodrow D acquired company equity through compensation awards. He received 6,903 shares of common stock at a price of $0, bringing his directly held common stock to 11,293 shares.
He was also granted 23,975 performance stock units at $0, following certification of performance conditions on February 9, 2026. These performance-based awards are scheduled to vest on March 3, 2026, subject to continued employment, while the restricted stock units vest in three equal annual installments beginning February 10, 2027.
Indivior Pharmaceuticals, Inc.’s Chief Financial Officer Ryan Preblick reported equity awards rather than open-market trades. He received a grant of 37,358 restricted stock units with a stated price of $0, increasing his directly held common stock to 317,940 shares after the award.
He was also credited with 113,510 performance stock units at an exercise price of $0. These relate to a conditional award originally granted on March 3, 2023, for 113,510 shares, with performance conditions certified on February 9, 2026. The award is scheduled to vest on March 3, 2026 and then remain subject to a further two-year holding period before the vested shares are released. The RSUs vest in three equal annual installments beginning February 10, 2027, conditioned on his continued service.
Indivior Pharmaceuticals’ Chief Legal Officer Jeffrey W. Burris reported new equity awards. He acquired 26,897 shares of common stock on February 10, 2026 through a grant of restricted stock units with a stated value of $0 per share, bringing his direct holdings to 27,657 common shares.
He was also granted 104,300 performance stock units on February 9, 2026. These units relate to a conditional award originally granted on March 3, 2023, for 104,300 shares, with performance conditions certified on February 9, 2026 and vesting on March 3, 2026, subject to continued employment. The new RSUs vest in three equal annual installments beginning February 10, 2027.
Indivior Pharmaceuticals, Inc. Chief Scientific Officer Christian Heidbreder reported equity awards in the form of stock-based compensation. On February 10, 2026, he acquired, via grant, 33,622 restricted stock units of common stock at a price of $0 and now directly holds 190,762 common shares.
On February 9, 2026, he was also granted 132,565 performance stock units at a price of $0. These performance stock units relate to a conditional award whose performance conditions were certified on February 9, 2026 and are scheduled to vest on March 3, 2026, subject to continued employment. The RSUs vest in three equal annual installments beginning February 10, 2027.
Indivior Pharmaceuticals, Inc. reported that its Chief Commercial Officer, Barry Patrick A, acquired 31,380 shares of common stock on February 10, 2026 through a grant of restricted stock units. These RSUs vest in three equal annual installments starting on February 10, 2027, subject to his continued service with the company.
Indivior Pharmaceuticals, Inc.’s Chief Executive Officer and director Joseph Ciaffoni reported receiving a grant of 79,976 shares of common stock in the form of restricted stock units at a price of $0 per share. Following this equity award, he beneficially owns 135,976 common shares directly.
The RSUs vest in three equal annual installments starting on February 10, 2027, the first anniversary of the grant. Each unit represents the right to receive one share of common stock, contingent on his continued service with the company.
Indivior Pharmaceuticals, Inc. director receives equity grant. Director Kingsley Stuart A reported an award of 3,722 shares of common stock on January 26, 2026, recorded at a price of $0 per share as a stock-based grant rather than a purchase.
The grant is in the form of Restricted Stock Units, each representing one future share of common stock. These RSUs vest on the day immediately before the first annual stockholders’ meeting following the grant date, as long as the director continues to serve on that date. After this award, the director beneficially owns 4,642 shares directly.
Indivior Pharmaceuticals director David E. Wheadon reported a grant of 5,955 shares of common stock on January 26, 2026, reflected as an acquisition at a price of $0 per share. After this equity grant, he beneficially owned 20,350 shares in total.
The grant consists of restricted stock units (RSUs), each representing a right to receive one share of common stock. These RSUs vest on the day immediately before the first annual stockholder meeting following the grant date, contingent on his continued service to Indivior through that vesting date.
Indivior Pharmaceuticals director receives equity grant. Director Ryan Barbara was granted 3,722 shares of Indivior Pharmaceuticals, Inc. common stock on January 26, 2026 as a stock-based award at a price of $0 per share. After this grant, Barbara beneficially owns 5,685 common shares in total.
The award is in the form of restricted stock units (RSUs), each representing the right to receive one share of common stock. These RSUs vest on the day immediately before the first annual stockholders’ meeting following the grant date, contingent on Barbara’s continued service to the company through that vesting date.
Indivior Pharmaceuticals director Daniel A. Ninivaggi received an equity grant through restricted stock units. On 01/26/2026 he was awarded 3,722 RSUs, recorded at a price of $0 per unit, increasing his beneficial ownership to 20,645 shares of common stock held directly.
The RSUs each represent a right to receive one share of Indivior common stock. They vest on the day immediately before the first annual meeting of stockholders following the grant date, as long as he continues to serve the company through that vesting date.
Indivior Pharmaceuticals, Inc. director Mark Stejbach reported a grant of 3,722 shares of common stock in the form of Restricted Stock Units on January 26, 2026 at a price of $0 per share. Following this award, he beneficially owns 20,569 common shares in total.
Each RSU represents the right to receive one share of common stock and will vest on the day immediately before the first annual stockholders’ meeting after the grant date, as long as Stejbach continues serving the company through that vesting date.
Indivior Pharmaceuticals, Inc. director Juliet Thompson reported a grant of 3,722 restricted stock units of common stock on January 26, 2026 at a price of $0 per share. After this award, she beneficially owns 7,572 shares directly, with an additional 5,775 shares held indirectly by her spouse. The RSUs vest on the day immediately before the first annual stockholders’ meeting following the grant date, subject to her continued service.
Indivior Pharmaceuticals director Keith Humphreys received an equity grant of 3,722 shares of common stock on January 26, 2026, reported as an acquisition at a price of $0 per share. Following this grant, he beneficially owns 9,524 shares directly.
The award is structured as restricted stock units (RSUs), with each RSU representing a contingent right to one share of common stock. The RSUs vest on the day immediately preceding the first annual stockholders’ meeting after the grant date, conditioned on his continued service as of the vesting date.
Indivior PLC director Ryan Barbara reported acquiring 775 Ordinary Shares on January 5, 2026 at a price of $35.3926 per share. These shares were received through participation in a Non-Executive Director Purchase Plan, under which a portion of director fees is taken in stock instead of cash. Following this transaction, Barbara beneficially owned 1,963 Ordinary Shares directly. This reflects a routine equity-based compensation election rather than an open-market investment decision.
Indivior PLC director Keith Humphreys reported acquiring additional ordinary shares in the company. On January 5, 2026, he obtained 775 ordinary shares at a price of $35.3926 per share, increasing his direct beneficial holdings to 5,802 shares.
The shares were acquired through Humphreys’ participation in a Non-Executive Director Purchase Plan, under which a portion of his fees for serving as a director is received in stock instead of cash. This filing reflects a compensation-related share purchase rather than an open-market discretionary trade.
Indivior PLC director Daniel A. Ninivaggi reported acquiring 775 ordinary shares of the company on January 5, 2026 at a price of $35.3926 per share.
The filing shows these shares were obtained through a Non-Executive Director Purchase Plan, where a portion of his director fees is taken in stock instead of cash. Following this transaction, he beneficially owned 16,923 ordinary shares, held directly.
Indivior plc director Mark Stejbach reported acquiring 775 ordinary shares of Indivior on January 5, 2026 at a price of $35.3926 per share. Following this transaction, he beneficially owns 16,847 ordinary shares, held directly.
According to the disclosure, the shares were received through a Non-Executive Director Purchase Plan, under which a portion of his director fees is taken in stock instead of cash. This reflects compensation taken in equity rather than an open-market investment decision.
Indivior PLC director David E. Wheadon reported acquiring additional ordinary shares of the company. On 01/05/2026, he obtained 1,771 ordinary shares at a price of $35.3926 per share, bringing his directly held stake to 14,395 shares after the transaction.
According to the disclosure, these shares were acquired through his participation in a Non-Executive Director Purchase Plan, under which he receives a portion of his director fees in stock instead of cash.